Nyxoah SA announced that it has begun commercial operations of its Genio hypoglossal neurostimulation system in the Netherlands, with the first bilateral implants performed at OLVG West in Amsterdam and Zuyderland Hospital in Heerlen on December 17, 2025. The early‑morning procedures, completed at 1:05 am ET, marked the company’s first successful implants in a new market and expanded its European footprint beyond the CE‑marked countries where it has already sold the device.
The Genio system’s design—bilateral, battery‑free, leadless, and fully MRI‑compatible—offers a less invasive alternative to continuous positive airway pressure (CPAP). The device is externally powered, allowing for easy upgrades via an external activation chip, and its bilateral stimulation improves tongue protrusion even in the supine position. These features address the key limitations of existing OSA therapies and position Genio as a compelling option for patients who struggle with CPAP compliance.
The Dutch OSA market is growing, driven by increasing patient demand for non‑CPAP solutions. While the article does not provide exact market‑share figures, the launch is expected to capture a share of a market that is expanding as more patients seek alternative therapies. Genio’s FDA approval for patients with complete concentric collapse (CCC) further widens its addressable market, as CCC patients are ineligible for many competitor devices.
Financially, Nyxoah reported Q3 2025 revenue of €2.0 million, a 56% year‑over‑year increase from €1.3 million in Q3 2024. However, the company’s operating loss widened to €24.4 million, reflecting higher commercialization costs, particularly in the United States. Nyxoah secured up to $77 million in financing in November 2025 to support its expansion, and its liquidity remains reasonable with a current ratio of 1.7 and a quick ratio of 1.41 as of September 30, 2025.
Chief Executive Officer Olivier Taelman emphasized the significance of the Dutch launch, stating that it “marks another important step in our European rollout and reflects growing adoption of our bilateral, externally powered Genio therapy.” He also highlighted the company’s partnership with leading Dutch centers and noted that the U.S. launch has already generated first revenue within the first month after FDA approval, underscoring the broader commercial momentum.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.